January 31st 2023
This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.
January 30th 2023
These diseases, exacerbated by poor water quality, sanitation, and health care access, are highlighted today.
January 27th 2023
The agency would like to begin using individual risk-based questions to reduce the risk of transfusion-transmitted HIV.
January 20th 2023
Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.
January 19th 2023
What is the hepatitis C treatment uptake among people who inject drugs?
COVID-19 Vaccination May Reduce Hepatitis B Surface Antigen
Some chronic hepatitis B patients experienced a dramatic decrease in hepatitis B surface antigen (HBsAg) after receiving a COVID-19 vaccine. Could there be a correlation?
Deadly Ebola Outbreak Is Over, Uganda Declares
After their first Sudan ebolavirus outbreak in 10 years, resulting in 164 cases, Uganda today announced the Ebola outbreak is over.
Would You Try Ceftriaxone for Methicillin-Susceptible Staphylococcus aureus Bacteremia?
This study was one of the largest to address the use of IV ceftriaxone in the context of MSSA bacteremia compared with cefazolin.
Investigational HBV Treatment Moves Goal from Suppression to Cure
Phase 2 trial with bepirovirsen demonstrates possibility of a functional cure of chronic hepatitis B infection that is sustained after treatment is discontinued.
Type I Interferon Response Linked to Resistance to HCV Infection
Resistance to hepatitis C infection may be much greater than previously thought, according to new research by investigators at Trinity College Dublin that revealed associated biological factors.
Measuring Disease Severity, Quality of Life in Japanese Hepatitis Patients
As viral hepatitis is the most common blood-transmitted infection globally, assessing the toll of hepatitis and hepatitis-related conditions is critical.
Breakthrough Therapy Bulevirtide was Safe, Effective, and Improved Quality of Life for Hepatitis Patients
Three posters on the subject were presented at The Liver Meeting and were among the meeting’s key presentation highlights called “Best of the Liver Meeting.”
Despite 60% Drop in Hepatitis B Treatment Efficacy, GSK Plans to Continue Trials
Initially, 28-29% of patients with chronic hepatitis B achieved undetectable virus levels after 24 weeks of treatment with GSK’s bepirovirsen, but this dropped to 9-10% of patients during a phase 2b trial.
Automatic Letters Help Boost Screenings for Hepatitis C
About a third of veterans who received a letter to get tested for hepatitis C did so, according to a study by the Veterans Affairs Greater Los Angeles Healthcare System.
Hepatitis C Can Be Cured in Young People Who Inject Drugs
Previously thought to be difficult or impossible, one study found HCV and drug use can be treated concurrently in young adults.
Positive Phase 1 Data Reported for Dengue Antiviral
Dengue is the most prevalent and important mosquito-borne virus in the world. Atea Pharmaceuticals presented positive data for their direct-acting dengue antiviral, AT-752.
Recent Research Indicates That We're Falling Short on HBV Elimination Targets
Organizations look at an agent-based model to assess the impact of vaccination, screening, and treatment on incidence and prevalence of HBV in Ontario, Canada.
With Ebola Outbreak, Uganda Places Two Regions in Lockdown
That country is trying to contain the virus to prevent further cases, as well as other African countries met to try to prevent an outbreak inside their own borders.
Among People with Hemophilia, HCV Prevention is Working, But Eradication Remains Elusive
A new review article suggests it is possible to eradicate hepatitis C virus infections among people with hemophilia, but it will take intense focus from public health agencies.
Hepatitis A Vaccination Efforts Can Reduce Spread
Hepatitis A infections occurred almost exclusively among adults in states with outbreaks.
Hepatitis C: Time to Treatment Varies by Insurance Type
“Too few persons are receiving timely treatment” with direct-acting antiviral for hepatitis C based on their first positive test result, the study authors wrote.
Bulevirtide Shows Promise for Treating Hepatitis
Bulevirtide, a first-in-class entry inhibitor, showed promise for the treatment of hepatitis B and hepatitis D coinfection, a phase 2 trial found.
To Eliminate Hepatitis by 2030, Hepatitis B Needs More Attention
Experts are advocating for occult hepatitis B to be spotlighted.
Uganda Declares Ebola Outbreak Caused by Sudan Virus
Uganda’s first Ebola outbreak in a decade raises concern due to its vaccine resistance.
Occult Hepatitis B Virus Infection: Underestimated Global Health Threat
Occult HBV infection is likely to go undetected in under-resourced regions of high HBV endemicity and confound WHO goal to eradicate the viral hepatitis by 2030.
Non-Targeted Screening Program Could Identify More HCV Infections
With an all-ready challenging patient population to treat, having a program to get more people into treatment can be helpful in an underserved group.
Higher Hepatitis Viral Load Increases Risk of Vertical Transmission
Among pregnant women coinfected with HIV, a higher hepatitis C viral load increased the likelihood of transmitting HCV to children.
HCV Not Associated With Myocarditis Risks for Young HIV Patients
However, according to one study the risk of heart inflammation increases with age and amplifies in patients with hepatitis C (HCV) compared to patients without HCV.
Greater Mortality and Disease Severity in Patients with Hepatitis B and COVID-19
A meta-analysis study shows having the comorbidity presents significant health risks for this patient population.
Kidney Transplant Survival is Unrelated to Donor HCV Status
The same 5-year survival rates with kidney transplants from HCV positive and negative donors supports revising HCV "penalty" in ranking donors.
Bridging Science and Education Together to Eliminate Hepatitis C
The Liver Health Initiative’s Thelma King Thiel, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, are a “Dynamic Duo” that are working together to bring about an end to this virus.
Accessible, Nonstigmatizing Care Clinic Had Better Hepatitis C Outcomes
Injection drug users who received accessible care treatment at a syringe service program were almost 3 times as likely to complete their hepatitis C treatment than people who received usual care.
Infectious Diseases Update: September 3, 2022
Catch up on all the important news and clinical care topics you may have missed this week.
Most People with HCV Infection Are Not Treated with Direct-Acting Antivirals
A new report underscores a persistent problem of patients not receiving antivirals despite their high curative rate.
HCV Reinfection Rare Among Patients Receiving Opioid Agonist Therapy
Rates of hepatitis C reinfection were low among people receiving opioid agonist therapy, according to a new study, which highlights the importance of risk reduction interventions and HCV treatment for people who inject drugs and people receiving opioid agonist therapy.
2 Clarke Drive Cranbury, NJ 08512